Vir Biotechnology Inc (VIR) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Vir Biotechnology Inc ( NASDAQ:VIR ) completed enrollment in Eclipse One, their first registrational phase 3 study for hepatitis Delta, ahead of schedule. The company plans to share a comprehensive data update for their PSMA targeted T-cell engager, VR 5,500, in the first quarter of 2026. Vir Biotechnology Inc ( NASDAQ:VIR ) dosed the first patient in their first line metastatic castration-resistant prostate cancer combination study. The company ended the third quarter with approximately $810.7 million in cash equivalents and investments, projecting their cash runway into mid-2027. The hepatitis Delta market represents a compelling commercial opportunity with approximately 61,000 RNA positive patients in the United States and 113,000 in EU markets. Negative Points Vir Biotechnology Inc ( NASDAQ:VIR ) reported a net loss of $163.1 million for the third qu
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vir Biotechnology (NASDAQ:VIR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare ConferenceBusiness Wire
- Global Leaders Driving The Future Of Healthcare At The 2025 Forbes Healthcare Summit [Forbes]Forbes
- Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile [YahoYaho
VIR
Earnings
- 11/5/25 - Miss
VIR
Analyst Actions
- 9/15/25 - HC Wainwright
VIR
Sec Filings
- 12/3/25 - Form 4
- 12/2/25 - Form 4
- 12/1/25 - Form 4
- VIR's page on the SEC website